- About us
- A new Institute dedicated to combating Leukemia
- Our news
- Support us
- You are
- Patients and relatives
- To be cared for and supported
- Become an expert patient
- Discover the Leukemia Institute
- Researchers
- Research
- Clinical trials
- Discover the Leukemia Institute
- Healthcare professionals
- Refer a patient
- Our clinical research
- Discover the Leukemia Institute
- Industry partners
- Discover the Leukemia Institute
- Translational research
- Donors
- Support us
- Discover the Leukemia Institute
- Care
- Patient care
- Our clinical services
- Our medical laboratories
- Patient Information
- Research
- Our research teams
- Our technological platforms
- Our clinical research
Adolescent and Young Adult Unit
Nicolas Boissel
Head of the department
Access and contact
Saint-Louis Hospital
1 avenue Claude-Vellefaux
75010 ParisDepartment activities
The Adolescent and Young adult Unit (AYA) was created in 2010 after the transfer of the Pediatric Unit from St Louis Hospital to Robert Debre Hospital.
The Unit is dedicated to patients aged from 15 to 25 years old with malignant hemopathy (acute leukemia, lymphoma) or non-malignant (aplastic anemia and sickle cell disease).
The Unit propose various therapies including intensive chemotherapy, allogeneic bone marrow transplantation and autologous transplantation, and innovative therapies like CAR-T cells.
The Unit has 16 single room with 12 beds for intensive care and 4 beds dedicated to allogeneic bone marrow transplantation. Patients with acute leukemia, lymphoma and aplastic anemia are treated there. Therapy includes intensive chemotherapy, immunotherapy, CAR-T cells, bone marrow transplantation (autologous and allogeneic).
Allogeneic transplantation can be indicated for patients with malignant hemopathy, severe aplastic anemia or severe sickle cell disease.
The outpatient unit has room dedicated to AYA patients for treatment that can be done during the day, transfusions and the follow up of patients with allogeneic bone marrow transplantation.
Patients are welcome for an expert advice or the follow up of an already treated hemopathy.
AYAs in transition, coming from a pediatric Unit and treated when they were young for an hemopathy that needs a prolonged follow up can be seen there.
Multidisciplinary Team Meetings
- Local Acute Leukemia MDT
Local Multidisciplinary Team Meeting: Collegial discussion of cases of AML or ALL patients managed at Saint-Louis Hospital.
Contact : nicolas.boissel@aphp.fr ; emmanuel.raffoux@aphp.fr ; lionel.ades@aphp.fr
- Acute Leukemia & Allogeneic Transplant MDT
Interregional Pediatric Multidisciplinary Team Meeting: Collegial discussion of cases of minor patients with AML or ALL with pediatric teams.
Contact : jean-hugues.dalle@aphp.fr
- Personalized Therapy for Relapsed/Refractory Acute Leukemia MDT
National Multidisciplinary Team Meeting: Collegial discussion of relapsed or refractory acute leukemia cases.
Contact : raphael.itzykson@aphp.fr ; phrousselot@ght78sud.fr
- Allogeneic Bone Marrow Transplant MDT
Local Multidisciplinary Team Meeting: Collegial discussion of cases with an indication for allogeneic bone marrow transplantation.
Contact : regis.peffaultdelatour@aphp.fr
- CAR-T Cells Pathway MDT
National Multidisciplinary Team Meeting: Collegial discussion of ALL cases with an indication for or treated with CAR-T cell therapy.
Contact : marie-emilie.dourthe@aphp.fr
- Local Lymphoma MDT
Local Multidisciplinary Team Meeting: Collegial discussion of lymphoma patient cases managed at Saint-Louis Hospital.
Contact : catherine.thieblemont@aphp.fr
- Lymphoma & Allogeneic Transplant MDT
Interregional Pediatric Multidisciplinary Team Meeting: Collegial discussion of minor patients with lymphoma with pediatric teams.
Contact : Veronique.minard@gustaveroussy.fr
- National Aplastic Anemia MDT
National Multidisciplinary Team Meeting: Collegial discussion of aplastic anemia patient cases.
Contact : regis.peffaultdelatour@aphp.fr
- National Sickle Cell Disease Transplant MDT
National Multidisciplinary Team Meeting: Collegial discussion of sickle cell disease patients with a potential indication for allogeneic transplant.
Contact : jean-hugues.dalle@aphp.fr
Team members
Pr Nicolas BoisselPU-PHDr Nathalie DhédinPHDr Florence RabianPHDr Florian ChevillonPHDr Mathieu JestinPHDr Victoire de MarcellusCCADr Loic VasseurCCADr Virginie Barraud-LangePH : Reproductive medicine specialist at the CECOS unit of Cochin Hospital: participates in two sessions per week (outpatient and inpatient consultations).Paramedical team
The paramedical team is coordinated by Celia Gounin and composed of 24 nurse, 12 auxiliary nurse and 2 specialized nurse (coordination nurse, Rachel Chamoux et Abdelatif Darrazi) who coordinate the path between city and hospital with ONCORIF and RIFHOP network.
A psychosocial support (Nora Naïditch et Laurie Leenknegt), educative support (École@l’Hôpital)) association and physical training (CAMI) is proposed since diagnosis.
Antoine Godeau, our animator, coordinate the activities supported by about 30 associations.
- Our technological platforms
- Our clinical services
- Discover the Leukemia Institute
- Translational research
- Our clinical research
- Clinical trials
- Become an expert patient
- To be cared for and supported
- Our news
- A new Institute dedicated to combating Leukemia
Featured research projects
Principal investigator: Pr N. Boissel
Phase I/IIA multicentric prospective study evaluating a treatment by CAR-T cells targeted 2 proteins on blasts surface (anti CD19 and CD22 CAR-T cells) in patients with relapse / refractory B-ALL. CAR-T cells will be produced academically in MEARY center (Saint Louis, APHP, Paris).
Principal investigator : Dr F. Rabian
Prospective multicentric national randomized study comparing a substitution by IgIV and an antibioprophylaxy in patients treated by anti CD19 CAR-T cells for a B ALL or a lymphoma.
Principal investigator: Pr N. Boissel
Phase I/IIA multicentric prospective study evaluating CAR-T binding CD33 protein on blasts surface (anti CD33 CAR-T cells) via an adaptator in patients with relapse / refractory AML/